Practical aspects of targeting IL-6 in COVID-19 disease.
C Calabrese, P Rajendram, GL Sacha… - … Clinic Journal of …, 2020 - europepmc.org
Interleukin 6 (IL-6) took center stage as a therapeutic target, given its role in the cytokine
storm phase of COVID-19. While IL-6 inhibitors have been widely used to treat a variety of …
storm phase of COVID-19. While IL-6 inhibitors have been widely used to treat a variety of …
Cytokines and COVID-19: friends or foes?
M Rokni, MR Hamblin, N Rezaei - Human vaccines & …, 2020 - Taylor & Francis
The cytokine storm following sepsis has been proven to be an important mechanism for
triggering acute respiratory distress syndrome, which is a fatal uncontrolled systemic …
triggering acute respiratory distress syndrome, which is a fatal uncontrolled systemic …
A deep look into COVID-19 severity through dynamic changes in blood cytokine levels
DA Kleymenov, EN Bykonia, LI Popova… - Frontiers in …, 2021 - frontiersin.org
An excessive inflammatory response to SARS-CoV-2 is thought to be a major cause of
disease severity and mortality in patients with COVID-19. Longitudinal analysis of cytokine …
disease severity and mortality in patients with COVID-19. Longitudinal analysis of cytokine …
[PDF][PDF] An update on cytokine storm in covid-19 infection: Pivotal to the survival of the patients
The immune system protects the host organism from exogenous and endogenouspathogens
. A finely tuned and balanced array of cytokines, coagulation factors, andcomplement …
. A finely tuned and balanced array of cytokines, coagulation factors, andcomplement …
Off-label therapy targeting pathogenic inflammation in COVID-19
L Romani, C Tomino, P Puccetti, E Garaci - Cell death discovery, 2020 - nature.com
The world is facing a pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) for which no proven specific therapies are available other than supportive ones …
CoV-2) for which no proven specific therapies are available other than supportive ones …
Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis
Background Numerous clinical trials and observational studies have investigated various
pharmacological agents as potential treatment for Coronavirus Disease 2019 (COVID-19) …
pharmacological agents as potential treatment for Coronavirus Disease 2019 (COVID-19) …
Cytokines and their relationship with the severity and prognosis of coronavirus disease 2019 (COVID-19): a retrospective cohort study
QQ Liu, A Cheng, Y Wang, H Li, L Hu, X Zhao… - BMJ open, 2020 - bmjopen.bmj.com
Objective To delineate the characteristics and clinical significance of plasma inflammatory
cytokines altered in COVID-19. Design Retrospective, single-centre cohort study. Setting …
cytokines altered in COVID-19. Design Retrospective, single-centre cohort study. Setting …
Cytokine profiles before and after immune modulation in hospitalized patients with COVID-19
We describe the cytokine profiles of a large cohort of hospitalized patients with moderate to
critical COVID-19, focusing on IL-6, sIL2R, and IL-10 levels before and after receiving …
critical COVID-19, focusing on IL-6, sIL2R, and IL-10 levels before and after receiving …
Consideration of severe coronavirus disease 2019 as viral sepsis and potential use of immune checkpoint inhibitors
Taking into consideration the multisystemic clinical and autopsy findings in “severe”
coronavirus disease 2019 patients, viral sepsis would be a more accurate term to describe …
coronavirus disease 2019 patients, viral sepsis would be a more accurate term to describe …
Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents
Abstract Background Coronavirus disease 2019 (COVID-19) is caused by Severe Acute
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2, previously named 2019-nCov), a novel …
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2, previously named 2019-nCov), a novel …